Search
for

    Sort by

    Research 91–120 of 1000+

    1. 5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis International Braz J Urol · 2018 · 4 citations
    2. WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH Therapeutic advances in urology · 2019 · 3 citations
    3. Complications of cataract surgery in Wistar rats undergoing treatment with tamsulosin Experimental and Therapeutic Medicine · 2018 · 3 citations
    4. Comparison of Intraoperative Blood Loss in Patients With Benign Prostatic Hyperplasia Undergoing Bipolar Transurethral Resection of the Prostate With and Without Preoperative Oral Finasteride Cureus · 2025 · 2 citations
    5. Purple corn extract improves benign prostatic hyperplasia by inhibiting 5 alpha-reductase type 2 and inflammation in testosterone propionate-induced rats Frontiers in Pharmacology · 2025 · 2 citations
    6. Pharmacophore and Atom Based 3D QSAR Studies on the Novel 5-Alpha-Reductase Inhibitors Indian Journal of Pharmaceutical Education · 2018 · 2 citations
    7. Re: Risk of Erectile Dysfunction Associated with Use of 5α-Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia: Population Based Studies Using the Clinical Practice Research Datalink European Urology · 2017 · 2 citations
    8. Hydroxychloroquine modulates the progression of experimentally induced benign prostatic hyperplasia in rats via targeting EGFR/ERK/STAT3 and AR/FOXO1/TRAIL pathways: computational and in vivo studies Scientific Reports · 2025 · 1 citations
    9. Efficacy and Safety of Thermobalancing Therapy in Men with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia was Confirmed by Clinical Trial ARC Journal of Urology · 2016 · 1 citations
    10. The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological Well-Being Current Sexual Health Reports · 2015 · 1 citations
    11. Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS) The Aging Male · 2026
    12. GC-MS Fatty Acid Profile and In silico Studies of Telfairia occidentalis Hook f. (Fluted Pumpkin) and Sphenostylis stenocarpa (African Yam bean) Seeds Oil on Human 5 Alpha Reductase II 2026
    13. Docosahexaenoic acid-acylated astaxanthin esters alleviate cisplatin- induced acute kidney injury by modulating the ferroptosis-related GPX4/xCT signaling pathway and reducing oxidative stress Food Science and Human Wellness · 2026
    14. The Experience of SARS-CoV-2 in Patients with Benign Prostatic Hyperplasia: Is There Any Correlation between Them? MAEDICA – a Journal of Clinical Medicine · 2025
    15. African Journal of Biomedical Research 2025
    16. Why are men with premature alopecia at higher risk of benign prostatic hyperplasia? And what about prostate cancer? Expert Review of Dermatology · 2012
    17. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. The Journal of Urology · 2005
    18. Estrogen and androgen signaling in the pathogenesis of BPH Nature reviews. Urology · 2011 · 149 citations
    19. Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer International Journal of Molecular Sciences · 2020 · 45 citations
    20. Simultaneous Target-Mediated Drug Disposition-Pharmacodynamic (TMDD-PD) Modeling of Finasteride and Dutasteride: Impact of Target Binding and Turnover on Non-linear Pharmacokinetics The AAPS Journal · 2025
    21. Tamsulosin and Solifenacin : A Dynamic Duo in BPH Management International Journal of Health and Medicine · 2025
    22. Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement Postgraduate Medicine · 2026
    23. Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia Research and Reports in Urology · 2019 · 26 citations
    24. Antiandrogenic activity of Riboflavin 5′-phosphate (FMN) in 22Rv1 and LNCaP human prostate cancer cell lines European Journal of Pharmacology · 2022 · 1 citations
    25. Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese Human Genomics · 2024 · 1 citations
    26. Antiandrogens: Clinical applications The Journal of Steroid Biochemistry and Molecular Biology · 1990 · 39 citations
    27. 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond European Urology Supplements · 2006 · 2 citations
    28. A histological study of the effect of panax ginseng versus finasteride on induced benign prostatic hyperplasia in rats with potentiality of spontaneous recovery The Egyptian Journal of Histology · 2020 · 1 citations
    29. 8주 지구성 훈련이 랫 전립선의 자가포식과 전립선비대증에 미치는 영향 2019
    30. Guideline for the primary care management of male lower urinary tract symptoms British Journal of Urology · 2004 · 97 citations